Physician profile
Todd Goodman
NPI 1538649579
$6,345.61
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,132 · 2022: $3,618 · 2023: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.52 | 2021-2023 | |
| Incyte Corporation | $831.22 | 2021-2023 | Opzelura |
| Janssen Biotech, INC. | $729.65 | 2021-2023 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $631.48 | 2021-2023 | |
| Genzyme Corporation | $541.59 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $464.12 | 2021-2023 | Dupixent |
| Pfizer INC. | $405.62 | 2021-2023 | |
| Amgen INC. | $338.55 | 2021-2023 | Otezla |
| Leo Pharma INC. | $290.72 | 2021-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $229.83 | 2021-2023 | Ilumya |
| Ucb, INC. | $145.89 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $85.03 | 2022-2023 | Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.83 | 2021-2023 | Jublia, Arazlo |
| Biofrontera INC. | $77.29 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $77.08 | 2021-2023 | Valchlor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $63.48 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $62.35 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $62.29 | 2022-2023 | Sotyktu |
| Galderma Laboratories, L.P. | $54.79 | 2021-2023 | Aklief, Oracea |
| Dermavant Sciences, INC. | $28.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2023 | |
| Epi Health, LLC | $22.51 | 2022 | |
| Kyowa Kirin, INC. | $20.10 | 2021 | |
| Journey Medical Corporation | $16.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.